United States: Nixing Discovery On Foreign Regulatory Submissions

Last Updated: September 4 2017
Article by Eric Alexander

The cases we typically write about focus on events after medical products have made their way through the applicable regulatory process and been marketed in the United States. The marketed product is used, people claim to have been injured by it, and they sue the manufacturer under various product liability theories. Often, in the course of seeking lots of discovery about the product and manufacturer, the plaintiffs in such cases will seek documents relating to foreign regulatory submissions and interaction. While there might be some relevance of such documents in some cases, getting and producing them tends a pretty big pain for reasons like privacy laws and translation. Plus, there is plenty of room for confusion given different regulatory standards in the United States and elsewhere around the world. Under the old version of Fed. R. Civ. P. 26, however, some degree of burdensome foreign discovery was pretty standard in large drug or device litigation. We have seen some signs (like here and here) that the new version of Rule 26 will be less friendly to plaintiffs seeking foreign fishing expeditions.

Schueneman v. Arena Pharms., Inc., No. 10cv1959-CAB (BLM), 2017 WL 3118738 (S.D. Cal. July 21, 2017) (Magistrate order), aff'd 2017 WL 3587961 (S.D. Cal. Aug. 21, 2017), is a securities case based on the allegation that the defendant pharmaceutical company defrauded investors by its representations about the likelihood that its new weight loss drug would get approved by FDA. The focus of the allegation is about tumors in a rat study that ultimately led to FDA issuing a non-approvable letter in October 2010. (As an aside, the drug was developed with a serotonin receptor subtype mechanism of action that was supposed to avoid heart valve issues seen with other weight loss drugs, litigation over which included allegations about a signal from tumors in a rat study—although the main plaintiff expert supporting that allegation did not get past Daubert.) The non-approval was made public at that time, although the plaintiff investors claim that they continue to have been misled for another three months. (The decisions do not mention either, but there was a fair amount of press on the rat study in September 2010 and the drug was ultimately approved, after more research, in June 2012.) In March 2012, the company submitted an application to the European Medicines Agency to try to market the drug in Europe. After some back and forth, the company withdrew that application in May 2013. (We are feeling parenthetical, so we will note that the withdrawal of the European application was also the subject of U.S. press attention, spurred on by Public Citizen, whose actions often seem coordinated with litigation efforts.) The plaintiffs sought every document conceivably related to the European application and its withdrawal, even though the allegations in the case were about earlier representations about FDA approval. Defendants balked and the fight was joined.

The requirement that discovery be "relevant to any party's claim or defense and proportional to the needs of the case" allowed for a more rational analysis that we have seen in the past on such disputes. Noting the "different standards utilized by the EMA and the FDA and the different time frames of the statements," the court required plaintiffs to "explain how documents presented to the EMA, especially those unrelated to the Rat Study, are relevant to the issue in this case of whether Defendants 'intentionally withheld information material to the market's assessment of whether and when the FDA would likely approve [L]ocaserin.'" 2017 WL 3118738, *4. Plaintiffs could not do that. They also could not establish proportionality, a burden now assigned to the proponent of the discovery (although the posture here was a motion to compel rather than a motion for protective order). Defendants had already produced or were producing lots of documents and estimated that a production of the documents at issue would take weeks and cost $80,000. In the past, such a cost estimate for even marginal documents sought from a drug company would probably not be seen as an undue expense sufficient to cut off the discovery. Now, in the age of proportionality, it is part of the puzzle:

Given the extremely broad discovery requests, including the fact that the requests are not limited to the Rat Study, the minimal relevance of the statements made after the class period in an application in the European Union involving drug standards that are different from those in the United States, and the large number of potentially responsive documents, the Court finds that requests 34-37 are not proportional to the needs of the case.

Id. Similar reasoning could be applied to disallow quite a few requests in drug and device product liability cases, particularly those on foreign regulatory discovery.

The defendant also forced plaintiffs to reveal the identity and contact information for six confidential informants relied upon for allegations in the complaint. Plaintiffs claimed attorney work product protection, which the magistrate rejected and the district court found to be so frivolous as to merit the award of expenses under Fed. R. Civ. P. 37(a)(5). Id. at **6-7; 2017 WL 3587961, *2. We cannot recall seeing a product liability plaintiff resist discovery on the basis for allegations in a complaint on a claim of work product protection, so we will not dwell on this holding—but the same reasoning would apply. Rather than just sound like homers and cheer when a drug company wins discovery motions, we will say that we like it when discovery is ordered on the actual allegations in the complaint and limited on issues outside of the allegations in the complaint.

This article is presented for informational purposes only and is not intended to constitute legal advice.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
 
In association with
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.

Disclaimer

Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.

Registration

Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.

Cookies

A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.

Links

This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.

Mail-A-Friend

If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.

Security

This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.